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Figure 1. Overall survival (OS) and event-free survival (EFS).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S95Methods: Pediatric patients (<21 years old, n¼34) on a
research protocol between 4/2006 and 6/2014 receiving
myeloablative conditioning (FLU/CY/13.2 Gy TBI) with or
without expanded CB HSPC (fresh or cryopreserved) were
included. Duration of initial hospitalization, use of opiate
pain medications (by continuous infusion or PCA), and use of
TPN were determined for each patient. All blood stream in-
fections occurring during initial hospitalization were also
recorded. Statistical comparisons between groups were
made with two-tailed, unpaired t-tests.
Results: 11 patients received expanded CBHSPC in addition to
1-2 unmanipulated CB units while a concurrent cohort of 23
patients received the same conditioning regimen without
expanded cell infusion. The mean time to neutrophil count of
500/mlwas16.5v.22.1days inpatients receivingexpandedcells
or not, respectively (p¼0.026). The mean duration of initial
hospitalization was 43.2 v. 55.6 days (p¼0.05) (Fig. 1), mean
duration for continuous opiate medications 9.7 v. 18.1 days
(p¼0.07), and mean time receiving TPN was 20.7 v. 30.1 days
(p¼0.06) (Fig. 2). Although not statistically signiﬁcant,
bacterial blood stream infections were identiﬁed during their
initial hospitalization in 3 patients receiving expanded CB
HSPC compared to 10 in the standard treatment group.
Conclusions: In addition to reduce time to ANC recovery,
these results suggest that administration of expanded CB
HSPC may signiﬁcantly reduce initial hospitalization and
may also reduce utilization of pain medications and nutri-
tional support in the pediatric population receiving CBT.
Thus, this cellular therapy has the potential to decrease the
risk of morbidity and mortality post-CBT by reducing
regimen related toxicities that directly result from delayed
hematopoietic recovery.93
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Department of Pediatrics, Columbia University, New York, NYBackground: Outcomes of matched sibling donor (MSD)
HCT for children with severe sickle cell disease have
improved with disease-free survival approaching 95%. As
outcomes have improved, interest in extending HCT to less
severely affected children has increased. However, there re-
mains little published experience in these patients. We
describe the largest multi-institutional retrospective review
of MSD HCT for patients with less severe SCD.
Methods: Patients who received MSD HCT at three centers
(Children’s National Medical Center, Children’s Healthcare of
Atlanta, and Columbia University Medical Center) between
January 2004eJune 2014 were eligible for inclusion in the
analysis. Thosewith severe complications, such as stroke and
recurrent acute chest syndrome, were excluded, using eligi-
bility criteria from a recently completed trial for severe SCD
(clinicaltrials.gov, NCT00968162).
Results: 25 patients (M/F: 13/12) met eligibility. 22 had HbSS
and 3 HbSC. The median age was 5.3 years (1-18.3). 8 patients
had no acute SCD related-complications. The most frequent
complication was vaso-occlusive pain 14/25 (56%) with a life-
timemedian of 1 crisis. 7 patients had splenic sequestration as
the only acute complication. Twenty-four received myeloa-
blative conditioning; 19 received BM, 3 cord blood (CB) and 3
BM + CB. Donor engraftment was achieved in all cases. Mean
peripheral whole blood or myeloid donor chimerismwas 94%
and 89%, at day +100 and +365 respectively. No patients suf-
fered severe regimen-related toxicities and none experienced
seizures, encephalopathy or other neurologic complications.
One patient developed acute GVHD (grade III), which respon-
ded to therapy. None developed chronic GVHD. Of the 17 pa-
tients who are a year or more from transplant, all are off
immune suppression. With a median follow-up of 23 months
(5-130 months) all patients are alive and free of SCD.
Conclusions: HLA MSD HCT for children with less severe
sickle cell appears to be highly effective. Given that nearly all
patients with SCD, regardless of their disease course during
childhood, will suffer serious morbidity as adults and have a
markedly shortened life expectancy, our experience suggests
HCT is appropriate for children with less severe disease.
Prospective studies involving these patients are needed.94
Neuroblastoma and Ewing’s Sarcoma Associated with
ROR1 Expression Can Be Effectively Targeted with NK
Cells Modiﬁed to Express an Anti ROR1 Chimeric Antigen
Receptor
Mona Elmacken 1, Aradhana Awasthi 1, Janet Ayello 1,
Carmella van de Ven 1, Wen Luo 1, Yanling Liao 1,
Stanley Riddell 2, Mitchell S. Cairo 1,3,4,5,6. 1 Pediatrics, New
Figure 1. Anti-R0R1 expression in transfected NK cells.
Figure 2. Anti-R0R1-CAR-NK cytotoxicity at 48 hours.
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Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S97Background: Metastatic solid tumors, especially neuroblas-
toma (NB) and Ewing’s sarcoma (ES) have dismal prognosis
(Perkins et al, PLoS One, 2014). Targeted cellular therapy with
T or NK cells modiﬁed with chimeric antigen receptors (CAR)
is a novel approach to chemo-resistant childhood solid tu-
mors (Grupp SA, Clin Cancer Res, 2012; Mackall C, Front Oncol,
2012). NK cells can be signiﬁcantly expanded by co-culture
with genetically engineered K562 cells overexpressing mb-
IL21 (Lee D, PLOS, 2012). Riddell and colleagues have iden-
tiﬁed ROR1 as a novel target on B cell tumors in which CARs
can be developed and utilized for targeted cellular therapy
(Riddell S, Blood, 2010).
Objective: To evaluate the in-vitro NK cytotoxic activity and
NK cell function following ex-vivo K562 mb-IL21expansion
of PBNK nucleofected with anti-ROR1-CAR against NB and
ES.
Material and Methods: PBNK were expanded with lethally
irradiated K562 Clone 9.mb-IL21 (generously provided by
Lee D, MD, PhD, MD Anderson, TX). Ex-vivo expanded PBNK
(ExPBNK) cells were electroporated with anti-ROR1-CD28-
41BBl-CD3z-tEGFRemRNA (Anti-ROR1-CAR was generously
provided by Riddell S, MD, Fred Hutch, WA). Anti-ROR1-CAR-
NK expression was detected using anti-mouse IgG, F(ab’)2.
Anti-ROR1-CAR-NK cytotoxicity was investigated against NB
(SKNBE2, SKNFI & SHSY5Y) and ES (TC71, EWS 502 & A673)
cell lines by DELFIA cytotoxicity assay at 10:1 E: T ratio.
Intracellular staining of CD107a, Interferon Gamma, Perforin
and GranzymeB was performed using a 10:1 E:T ratio of anti-
ROR1-CAR-NK cells against tumor targets & analyzed on the
MACSQuant ﬂow cytometer.
Results: NB and ES cell lines expressed ROR1 (50.215.6%)
and (31.512%), respectively. Expansion of NK cells was
signiﬁcantly increased 3988435 fold (p¼0.00001) at day
14 vs day 0. Nucleofection success was measured by F(ab’)2
expression and showed a signiﬁcant increase in anti-
ROR1-CAR- (88.31.69%) vs Mock-electroporated NK cell
populations (8.16.9%) p¼ 0.0001 at 36-48 hours (Figure 1).
ROR1 negative A673 served as negative control. Anti-ROR1-
CAR-NK signiﬁcantly increased cell lysis compared to
Mock NK (93.11.9% vs 62.85.2%, p¼0.0008) against
ROR1expressing cell lines at 10:1 ET ratio (Figure 2).
Similarly, expression of CD107a (46.92.2 vs 26.93%)
p¼0.0004, Interferon Gamma (36.912.4vs15.36.9%)
p¼0.008, GranzymeB (62.84.4 vs 46.67.7%) p¼0.003,
and Perforin (50.58 vs 32.714.1%) p¼0.004 were
signiﬁcantly increased in anti-ROR1-CAR-NK vs Mock-NK
cells at 10:1 E:T ratio against the ROR1 expressing targets.
Conclusion: Anti-ROR1-CAR-ex-PBNK cells had signiﬁcant
enhanced cytotoxicity and signiﬁcantly increased CD107a,
Interferon Gamma, Perforin, and GranzymeB activity against
ROR1 expressing pediatric solid tumors. Future directions
include investigating the ex-PBNK anti–ROR1-CAR cells in-
vivo against ROR1 expressing pediatric solid tumors.95
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Hematopoietic Stem Cell Transplantation (HSCT) is curative in
a large number of primary immunodeﬁciencies (PID). The ﬁrst
transplant in PID in Brazil was held in 1992 at the Hospital de
Clínicas da Universidade Federal do Paraná. Since then, in
Brazil, only few centers have performed transplants in these
pathologies. Objective: Retrospective analysis of outcomes of
HSCT performed in patients with PID in 10 Brazilian centers
participating in theworking group of pediatric transplantation
of the Brazilian Society of BMT (SBTMO). From 1992 to April
2014, 166 patients underwent HSCT on PID in 10 different
centers in Brazil, mostly in the Hospital of UFPR (n ¼ 90), fol-
lowed by the Hospital Israelita Albert Einstein (n¼ 27) and the
other centers with 10 or fewer. Most patients were male (M ¼
130, F¼ 36), andmost patients had age lower than3 years (n¼
119). The diagnoses were distributed among: Wiskott-Aldrich
syndrome (n¼ 56); Severe Combined Immunodeﬁciency (n¼
52); Chronic granulomatous disease (n¼ 14); Familiar Hemo-
phagocytic lymphohistiocytosis (n ¼ 13); Chediak-Higashi
Syndrome (n ¼ 12); Hyper-IgM syndrome (n ¼ 5); Severe
congenital neutropenia (n ¼ 5); IPEX syndrome (n ¼ 3); com-
bined immunodeﬁciency disease (n¼ 2); Leukocyte Adhesion
Deﬁciency (n ¼ 2); Deﬁciency of IFN-gamma (n ¼ 1) and
Griscelli syndrome (n ¼ 1). Thirty-two patients received
transplants from identical sibling donors, 112 unrelated do-
nors, and 22 other family donors (10/10 compatible or hap-
loidentical). Graftwas bonemarrow in 84 cases, umbilical cord
blood in 78 cases and 4 patients received stem cells from pe-
ripheral blood. Ninety-nine patients received myeloablative
transplants (including busulfan>8mg/Kg), 55 patients
received reduced toxicity conditioning and 12 patients
received no conditioning. The prophylaxis of graft-versus-host
disease was performed with cyclosporine A in most cases,
associated with mycophenolate mofetil, methotrexate or ste-
roids. Overall survival was 68.7% at 3 years. In univariate
analysis, there was no statistical difference between gender,
diagnosis, age at HSCT, year of transplant, source of cells, or
donor type. Among the most frequent pathologies groups,
analysis was done in 2 groups, the severe combined immu-
nodeﬁciency (n¼ 52) and theWiskott-Aldrich syndrome (n¼
56) Syndrome. In these subgroups, the overall survival at 3
years was 60% and 79%, respectively.
Conclusion: This is the ﬁrst survey made on transplants on
primary immunodeﬁciencies in Brazil. Despite the difﬁ-
culties in diagnosing and referral of these children for special
treatment in our country, we have seen that the overall
survival of our patients is not different than those reported in
international studies in Europe or North America. This survey
is extremely important to have the results of these cases in
Brazil, and identify areas to improve the outcomes of trans-
plants in lower income countries.
